Soligenix is continuously looking to expand its clinical development programs, and is seeking additional partners to out-license all or portions of our programs. We are keen to advance our products through development and onto the market in as many indications as possible.
We would consider the following types of partnering possibilities with regard to each of our programs:
SGX94 is a proprietary 5-amino acid peptide for systemic delivery that regulates the innate immune system to reduce inflammation, eliminate infection and enhance tissue healing. Soligenix is seeking partners for therapeutic applications of SGX94 in all territories of the world.
oral Beclomethasone 17,21-dipropionate (BDP) is a highly potent, topically active corticosteroid with a local effect on inflamed tissue provides a potent topical anti-inflammatory effect with less systemic toxicity than a comparably effective systemic corticosteroid. Soligenix is seeking partners for therapeutic applications of oral BDP such as pediatric Crohn’s disease and acute radiation enteritis in all territories of the world.
ThermoVax®, proprietary vaccine thermostabilization technology, recent study results indicated stability of prototype vaccines that have been kept at elevated temperatures retained effectiveness and potency while stored at 40 degrees Celsius (in excess of three months). Soligenix is seeking development partners interested in establishing heat stable version of their existing vaccines. These could take the form of joint venture/co-development alliances or sublicenses.
Soligenix is seeking development partners for its ricin toxin vaccine (RiVax®) and its acute radiation syndrome therapeutic Orbeshield® in all territories of the world. These could take the form of joint venture/co-development alliances or sublicenses.
Please direct inquiries to:
Chief Financial Officer
29 Emmons Drive – Suite B-10
Princeton, NJ 08540
Phone: (609) 538-8200
Fax: (609) 452-6467